SynthesisNature communications2016
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.
Registry-linked trialAbstract readMeta-Analysis
In one paragraph
Synthesis in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05539079 (A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance), which is not on this map. Cited by 116 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance
Who cites it
116 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization.International journal of molecular sciences · 2023Pooled it
- Pooled it
- A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.Blood advances · 2020Pooled it
- Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.Human genomics · 2019Pooled it
- Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.Nature communications · 2018Pooled it
- Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients.Cancer medicine · 2018Pooled it
- A prospective study of familial predisposition to plasma cell dyscrasias.Blood advances · 2026Article
- Article
- Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry.Blood cancer discovery · 2026Article
- ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance.International journal of cancer · 2026Article
- Deciphering the genetic underlying causes of sex differences in multiple myeloma incidence and mortality.HGG advances · 2026Article
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- WAC is associated with malignant phenotypes and Wnt/β-catenin pathway activity in liver cancer cells.Translational cancer research · 2026Article
- NAT10 maintains stem cell homeostasis by mitigating mRNA decay through an acNature cell biology · 2026Article
- Review
- Article
- Smohaze-Upregulated RFWD3 Competes with TRIM24 to Stabilize TREX1 and Reduce Cytosolic dsDNA in Non-Small Cell Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Exosome-transmitted HSPA9 facilitates bortezomib resistance by targeting TRIP13/USP1 signaling in multiple myeloma.Cell communication and signaling : CCS · 2025Article
- Exploration of the Prognostic Markers of Multiple Myeloma Based on Cuproptosis-Related Genes.Cancer reports (Hoboken, N.J.) · 2025Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
58 authors.
Jonathan S MitchellDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
Ni LiDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
Niels WeinholdMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Asta FörstiGerman Cancer Research Center, 69120 Heidelberg, Germany.
Mina AliHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84 Lund, Sweden.
Mark van DuinDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA Rotterdam, The Netherlands.
Gudmar ThorleifssondeCODE Genetics, Sturlugata 8, IS-101 Reykjavik, Iceland.
David C JohnsonDivision of Molecular Pathology, The Institute of Cancer Research, Surrey SM2 5NG, UK.ORCID 0000-0003-0887-3343
Bowang ChenGerman Cancer Research Center, 69120 Heidelberg, Germany.
Britt-Marie HalvarssonHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84 Lund, Sweden.
Daniel F GudbjartssondeCODE Genetics, Sturlugata 8, IS-101 Reykjavik, Iceland.
Rowan KuiperDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA Rotterdam, The Netherlands.
Owen W StephensMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Uta BertschDepartment of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, Germany.
Peter BroderickDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.ORCID 0000-0002-8348-5829
Chiara CampoGerman Cancer Research Center, 69120 Heidelberg, Germany.
Hermann EinseleUniversity Clinic of Würzburg, 97080 Würzburg, Germany.
Walter A GregoryClinical Trials Research Unit, University of Leeds, Leeds LS2 9PH, UK.
Urban GullbergHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84 Lund, Sweden.
Marc HenrionDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.ORCID 0000-0003-1242-839X
Jens HillengassDepartment of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, Germany.
Per HoffmannInstitute of Human Genetics, University of Bonn, D-53127 Bonn, Germany.
Graham H JacksonRoyal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK.
Ellinor JohnssonHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84 Lund, Sweden.
Magnus JöudHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84 Lund, Sweden.
Sigurður Y KristinssonDepartment of Hematology, Landspitali, National University Hospital of Iceland, IS-101 Reykjavik, Iceland.
Stig LenhoffHematology Clinic, Skåne University Hospital, SE-221 85 Lund, Sweden.
Oleg LeniveDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
Ulf-Henrik MellqvistSection of Hematology, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.
Gabriele MiglioriniDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
Hareth NahiCenter for Hematology and Regenerative Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Sven NelanderRudbeck Laboratory, Department of Immunology, Pathology and Genetics, Uppsala University, SE-751 05 Uppsala, Sweden.
Jolanta NickelDepartment of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, Germany.
Markus M NöthenInstitute of Human Genetics, University of Bonn, D-53127 Bonn, Germany.
Thorunn RafnardeCODE Genetics, Sturlugata 8, IS-101 Reykjavik, Iceland.
Fiona M RossWessex Regional Genetics Laboratory, University of Southampton, Salisbury SP2 8BJ, UK.
Miguel Inacio da Silva FilhoGerman Cancer Research Center, 69120 Heidelberg, Germany.
Bhairavi SwaminathanHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84 Lund, Sweden.
Hauke ThomsenGerman Cancer Research Center, 69120 Heidelberg, Germany.ORCID 0000-0001-5951-3116
Ingemar TuressonHematology Clinic, Skåne University Hospital, SE-221 85 Lund, Sweden.
Annette VangstedDepartment of Haematology, University Hospital of Copenhagen at Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Ulla VogelNational Research Centre for the Working Environment, DK-2100 Copenhagen, Denmark.
Anders WaageDepartment of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Box 8905, N-7491 Trondheim, Norway.
Brian A WalkerMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Anna-Karin WihlborgHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84 Lund, Sweden.
Annemiek BroylDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA Rotterdam, The Netherlands.
Faith E DaviesMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Unnur ThorsteinsdottirdeCODE Genetics, Sturlugata 8, IS-101 Reykjavik, Iceland.
Christian LangerDepartment of Internal Medicine III, University of Ulm, D-89081 Ulm, Germany.
Markus HanssonHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84 Lund, Sweden.ORCID 0000-0002-7715-4548
Martin KaiserDivision of Molecular Pathology, The Institute of Cancer Research, Surrey SM2 5NG, UK.
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA Rotterdam, The Netherlands.
Kari StefanssondeCODE Genetics, Sturlugata 8, IS-101 Reykjavik, Iceland.
Gareth J MorganMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Hartmut GoldschmidtDepartment of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, Germany.
Kari HemminkiGerman Cancer Research Center, 69120 Heidelberg, Germany.
Björn NilssonHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84 Lund, Sweden.
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
Funding
Tumor Cell-Microenvironment Interactions in the Molecular Pathogenesis of MultiplP01CA055819 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI YACCOBY, SHMUEL · 1993 to 2013
$49.7MMedical Research Council G0100132Medical Research Council MC_PC_15018NCI NIH HHS P01 CA055819Wellcome Trust
Abstract
Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis. Genome-wide association studies have transformed our understanding of MM predisposition, but individual studies have had limited power to discover risk loci. Here we perform a meta-analysis of these GWAS, add a new GWAS and perform replication analyses resulting in 9,866 cases and 239,188 controls. We confirm all nine known risk loci and discover eight new loci at 6p22.3 (rs34229995, P=1.31 × 10(-8)), 6q21 (rs9372120, P=9.09 × 10(-15)), 7q36.1 (rs7781265, P=9.71 × 10(-9)), 8q24.21 (rs1948915, P=4.20 × 10(-11)), 9p21.3 (rs2811710, P=1.72 × 10(-13)), 10p12.1 (rs2790457, P=1.77 × 10(-8)), 16q23.1 (rs7193541, P=5.00 × 10(-12)) and 20q13.13 (rs6066835, P=1.36 × 10(-13)), which localize in or near to JARID2, ATG5, SMARCD3, CCAT1, CDKN2A, WAC, RFWD3 and PREX1. These findings provide additional support for a polygenic model of MM and insight into the biological basis of tumour development.
Indexed as
Adaptor Proteins, Signal TransducingAutophagy-Related Protein 5Case-Control StudiesChromosomal Proteins, Non-HistoneCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Genetic Predisposition to DiseaseGenome-Wide Association StudyGuanine Nucleotide Exchange FactorsHumansMultiple MyelomaPolycomb Repressive Complex 2RNA, Long NoncodingTranscription FactorsUbiquitin-Protein LigasesAdaptor Proteins, Signal TransducingATG5 protein, humanAutophagy-Related Protein 5CCAT1 long noncoding RNA, humanCDKN2A protein, humanChromosomal Proteins, Non-HistoneCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Guanine Nucleotide Exchange FactorsJARID2 protein, humanPolycomb Repressive Complex 2PREX1 protein, humanRFWD3 protein, humanRNA, Long NoncodingSMARCD3 protein, humanTranscription FactorsUbiquitin-Protein LigasesWAC protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05539079ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.